Investors

Overview

Company Profile

We are a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what we believe to be a key underlying cause of Alzheimer’s and other degenerative diseases. Our approach is based on the seminal discovery of the presence of Porphyromonas gingivalis, or P. gingivalis, and its secreted toxic virulence factor proteases, called gingipains, in the brains of greater than 90% of more than 100 Alzheimer’s patients observed across multiple studies to date. Additionally, we have observed that P. gingivalis infection causes Alzheimer’s pathology in animal models, and these effects have been successfully treated with a gingipain inhibitor in preclinical studies.

Our proprietary lead drug candidate, COR388, is an orally-administered, brain-penetrating small molecule gingipain protease inhibitor. COR388 was well-tolerated with no concerning safety signals in our Phase 1a and Phase 1b clinical trials conducted to date, which enrolled a total of 67 subjects, including nine patients with mild to moderate Alzheimer’s disease. We plan to initiate a global Phase 2/3 clinical trial of COR388, called the GAIN trial, in mild to moderate Alzheimer’s patients in the second quarter of 2019 and expect top-line results by the end of 2021.

Investor Relations

Cortexyme, Inc.

269 East Grand Ave.

South San Francisco, CA 94080

(415) 910-5717

ir@cortexyme.com

Stock Information

Recent News

April 16, 2019
Cortexyme Announces Phase 2/3 Clinical Trial Based On Transformational Understanding Of Alzheimer’s Disease
April 16, 2019
Cortexyme Announces Phase 2/3 Clinical Trial Based On Transformational Understanding Of Alzheimer’s Disease
April 16, 2019
Cortexyme Announces Phase 2/3 Clinical Trial Based On Transformational Understanding Of Alzheimer’s Disease
April 16, 2019
Cortexyme Announces Phase 2/3 Clinical Trial Based On Transformational Understanding Of Alzheimer’s Disease